Prospective, Randomized Phase II Study Comparing Two Elution Rates of Glaukos Travoprost Intraocular Implants to Timolol Maleate Ophthalmic Solution, USP, 0.5%

Trial Profile

Prospective, Randomized Phase II Study Comparing Two Elution Rates of Glaukos Travoprost Intraocular Implants to Timolol Maleate Ophthalmic Solution, USP, 0.5%

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Travoprost (Primary) ; Timolol
  • Indications Glaucoma
  • Focus Therapeutic Use
  • Sponsors Glaukos Corporation
  • Most Recent Events

    • 14 Sep 2017 According to a Glaukos Corporation media release, the subjects will be followed through three years.
    • 14 Sep 2017 Preliminary results published in a Glaukos Corporation media release.
    • 15 Mar 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top